Crowdonomics
All companies
Venomyx Therapeutics logo

Venomyx Therapeutics

Operating

Venomyx, Inc

Visit website

EpiPen for snakebites: the antivenom of tomorrow!

Valuation cap ⓘ
$5.0M
As of Mar 2019 · from Reg CF Offering (2018) · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$269,844
Across 1 round since 2018

Financials

FY2016–FY2017 · from SEC filings · hover any figure for its source
$0
−$116K
2016
$0
−$158K
2017
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2016
FY2017
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$116,136
-$158,248
Taxes paid
$0
$0
Balance sheet
Cash
$95,158
$10,226
Accounts receivable
$0
$0
Total assets
$115,158
$155,226
Short-term debt
$0
$0
Long-term debt
$100,000
$202,500
Total liabilities
$100,000
$202,500
Other
Headcount
—
3

Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.

Valuation over rounds

Post-money = pre-money + amount raised · caps marked
$5.0M
Valuation cap
Reg CF Offering (2018)

A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.

Fundraising history

Reg CF Offering (2018)ClosedReg CF · SAFE · via WeFunder
Raised $269.8K / $107KInvestors 473Valuation cap $5M

Team

2 people
Daniel DempseyFounder
Founder and CEO
Deepankar RoyFounder
Founder and COO

Names and titles as disclosed on SEC Form C. Bios and photos come from the platform campaign page and may be out of date.

Reg CF annual-report compliance

Delinquent

Filed 0 of 8 annual reports (FY2018–FY2025)

Missing: 2018, 2019, 2020, 2021, 2022, 2023, 2024, 2025

473 investors
holder-count proxy

Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.

SEC filings

  • Form C/AApr 24, 20190001670254-19-000260
    EDGAR
  • Form C/AApr 10, 20190001670254-19-000187
    EDGAR
  • Form COct 23, 20180001670254-18-000499
    EDGAR
Source: ManualCIK 0001755717

About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.